Defining Target Vancomycin Trough Concentrations for Treating Staphylococcus aureus Infection in Infants Aged 0 to 90 Days

JAMA Pediatr. 2019 Aug 1;173(8):791-793. doi: 10.1001/jamapediatrics.2019.1488.


This study analyzes data from a randomized clinical trial in infants 90 days and younger to develop a pharmacokinetic model to aid physicians in maintaining minimum inhibitory concentrations of vancomycin in young infants with Staphylococcus aureus infection.